Antidiarrhoeals Global Market Report 2022 Featuring GSK, Actelion, Perrigo, Lupin and Glenmark Pharmaceuticals, Merck & Co., Pfizer, Proctor & Gamble, Sanofi Aventis and Bayer - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Antidiarrhoeals Global Market Report 2022, Drug Class, Application, Type" report has been added to ResearchAndMarkets.com's offering.
The global antidiarrhoeals market is expected to grow from $3.58 billion in 2021 to $3.78 billion in 2022 at a compound annual growth rate (CAGR) of 5.5%. The market is expected to reach $4.39 billion in 2026 at a CAGR of 3.8%.
Major players in the antidiarrhoeals market are GlaxoSmithKline, Actelion, Perrigo, Lupin and Glenmark Pharmaceuticals, Merck & Co., Pfizer, Proctor & Gamble, Sanofi Aventis and Bayer.
The antidiarrhoeal drugs market consists of sale of antidiarrhoeal drugs and related services. Diarrhea is a disease affecting digestive parts of the body such as stomach, large intestine and rectum, esophagus, liver, gallbladder and pancreas and causes loose, watery bowel movements. Loperamide and bismuth subsalicylate are some examples of antidiarrhoeal drugs.
The main classes of antidiarrhoeals drugs are mucosal protectants and motility modifying drugs. Mucosal protective agents are drugs which safeguard the stomach's mucosal lining from gastric acid and are employed to cure peptic ulcers. The different types include OTC drugs, prescription drugs and is used by adults and children.
Rise in the number of diarrhea cases significantly contributes to the growth of antidiarrhoeal drugs market. According to UNICEF, diarrhea was the second leading cause of death among children under the age of 5 years that is responsible for killing 760,000 children every year. Increasing number of diarrhoeal cases increases the demand for antidiarrhoeal drugs.
Increase in the use of biologics medicines poses to be a restraint to the antidiarrhoeal market. Biologics are medicines derived from living organisms like human beings, animals or other microorganisms using biotechnology and are composed of proteins, sugar, nucleic acids or a combination of each of these substances. Due to their ability to target inaccessible parts using small-molecule therapies, biologics are being preferred over the traditional chemical drugs.
This shift is restricting the antidiarrhoeal drugs market hampering the growth of the market. For example, to treat Crohn's Disease, antidiarrhoeal medications were being used previously, but with the advent of biologics, demand for antidiarrhoeal diseases has subsided.
Major companies in the antidiarrhoeal drug market are merging with other companies in the market to increase their reach and market share. Companies merge with or acquire other companies to expand their market share, diversify their product portfolio, or acquire new technologies. For instance, GlaxoSmithKline agreed to acquire Novartis AG's 36.5% stake in consumer healthcare business for $ 13 billion with an aim to expand the market.
The antidiarrhoeal drug industry is governed with regulatory frameworks by agencies such as US Food and Drug Administration Agency (FDA). FDA's guidelines for antidiarrhoeal drugs are mentioned within the CFR's (Code for Federal Regulations) title number 21 under part 335 which gives guidelines for the over the counter (OTC) human use of the antidiarrhoeal drugs.
The subpart C of the regulation focuses on the labeling aspect of such drugs and mandates a statement of identity, which identifies the product is to be used for diarrhea in order to avoid any improper use of the drug. The FDA also regulates the warnings and directions of use of the drugs which are to be printed on cover of these drugs.
In March 2020, Arcadia Consumer Healthcare, Inc., a USA based pharmaceutical company acquired Kaopectate brand from Sanofi for an undisclosed amount. This acquisition enhanced Sanofi's product portfolio by providing consumers with simple, efficacious, and high-quality solutions. Sanofi, a France based biopharmaceutical company focused on human health.
The countries covered in the antidiarrhoeals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Key Topics Covered:
1. Executive Summary
2. Anti-diarrhoeal Drugs Market Characteristics
3. Anti-diarrhoeal Drugs Market Trends And Strategies
4. Impact Of COVID-19 On Anti-diarrhoeal Drugs
5. Anti-diarrhoeal Drugs Market Size And Growth
5.1. Global Anti-diarrhoeal Drugs Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Anti-diarrhoeal Drugs Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Anti-diarrhoeal Drugs Market Segmentation
6.1. Global Anti-diarrhoeal Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
- Mucosal Protectants
- Motility Modifying Drugs
6.2. Global Anti-diarrhoeal Drugs Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
6.3. Global Anti-diarrhoeal Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
- OTC drugs
- Prescription Drugs
7. Anti-diarrhoeal Drugs Market Regional And Country Analysis
7.1. Global Anti-diarrhoeal Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Anti-diarrhoeal Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
- Glenmark Pharmaceuticals
- Merck & Co.
- Proctor & Gamble
- Sanofi Aventis
- Johnson and Johnson
- Kroger Company
- Harmon Store Inc.
- Great Lakes Wholesale Marketing and Sales
- Geri Care Pharmaceutical Corp.
- Freds Inc.
- DOLGEN Corporation
- CVS Pharmacy
- American Sales Company
- Cardinal Health
- Bedrock LLC
- Greenbrier International
- Good Neighbour Pharmacy
For more information about this report visit https://www.researchandmarkets.com/r/oabvhz
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900